Frequency and treatment of urinary tract infection in children subjected to urine culture, in Sana'a, Yemen.
BACKGROUND
This study was carried out to estimate the frequency of urinary tract infection among children subjected to urine culture presenting to Sam Hospital, Sana'a city, Yemen and to determine the susceptibility of the isolated bacteria to the antibiotics.


METHODS
Record-based study was done in Sam hospital in Sana'a city Yemen during three years 1/1/1999-31/12/2001. Out of 70,500 patients seen for different causes through that period 820 (1.16%) having urinary symptoms (fever, rigor, vomiting, frequency or screams during the act of urination) were subjected to urine culture. Data about age and sex were also collected.


RESULTS
Frequency of urinary tract infections among children examined by urine culture was 36.8% (n=302), with mean age of 7.6 years. 272 (90.1%) of them were females, and 30 (9.9%) were males. More than half 154 (51%) of infected patients were less than three years old. The isolated bacteria was Escherichia coli 201 (66.3%) followed by Staphylococcus suprofyticus 45 (14.9%), Proteus spp 15 (4.9%), Klebsiella 12 (3.9%) then Enterococcus spp 12 (3.9%). Sensitivity of E. coli to Nalidexic acid was 70%, to Amoxicillin/Clavulanic acid was 29.9%, to Co-trimoxasole was 16.4%, and to Nitrofurantoin was 15.9%.


CONCLUSIONS
The majority of the infected patients were females and the highest frequency of the disease was in the first three years of age. The most common isolated microorganism was E. coli followed by Staphylococcus suprofyticus, Proteus spp, then Enterococcus spp. The highly active antibiotic for most organisms isolated was Nalidexic acid, then amoxicillin/clavulanic acid. Nalidexic acid can be used as a first line empiric treatment and/or prophylaxis of UTI in children.
Mohanna
Mabrook Aidah Bin
MA
Department of Pediatrics, Faculty of Medicine and Health Sciences, Sana'a University, Yemen. mabrookmohanna@yahoo.com
Raja'a
Yahia Ahmed
YA
D000293:Adolescent; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009268:Nalidixic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D012189:Retrospective Studies; D016482:Urinalysis / Q000191:economics / Q000706:statistics & numerical data; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D015006:Yemen / Q000453:epidemiology
D000890:Anti-Infective Agents; D009268:Nalidixic Acid